Physioplus Raises at an $800,000 Valuation, Less Than a Rival's Single Round

In this storyPhysioplus HealthcareHHBF India

Physioplus Healthcare has raised a strategic seed investment from HBF India at a valuation of $800,000, roughly ₹7.6 crore. The amount has not been disclosed. HBF Direct Limited's managing director Sachin K Sheoran announced the investment on World Physiotherapy Day.

The Jaipur company connects patients with certified physiotherapists through its platform, and offers physiotherapy discovery, consultations, patient assessments, clinical documentation and technology-enabled monitoring. It combines digital practice management, patient data and remote monitoring to support physiotherapy and rehabilitation, across chronic pain, musculoskeletal conditions, sports injuries and post-surgery rehabilitation.

Samit Saxena, Jaswant Singh and Madhukar Pareek co-founded it, with the operating entity incorporated in Jaipur in July 2022. The company began with a sports focus, working with fitness centres and sports academies to make physiotherapy more accessible to athletes, before broadening into general rehabilitation. It says it has onboarded more than 1,000 patients.

Saxena has described the company's origin as a ₹3,000-a-year idea in 2021, and its purpose as making technology relevant to the working clinician: helping a physiotherapist assess better, measure outcomes, demonstrate progress and build patient trust rather than adding another device or app. HBF framed the investment around a shift from therapy delivered to recovery demonstrated.

The proceeds go towards strengthening the technology platform, expanding the physiotherapist network and increasing presence across India.

Other companies in the segment have raised considerably more. FlexifyMe raised $2.4 million in a pre-Series A round led by IvyCap Ventures and Signal Ventures last year to scale its online physiotherapy platform. Stance Health raised $1 million in pre-seed funding in 2025 for its technology-enabled musculoskeletal care model, and Rebee Health secured investment from 1337 Ventures the same year to expand a wearable sensor-based digital physiotherapy system.

Ask a physiotherapist why treatment fails and the answer is almost never about technique. It is that the patient stopped coming.

Physiotherapy is unusual among medical disciplines in how much of the work happens when the clinician is not present. An hour in the clinic is followed by a week of exercises the patient is supposed to do alone, and the recovery depends far more on that week than on the hour. The evidence on how often those exercises actually get done is consistently poor, across countries and conditions, and it is the single largest determinant of whether someone recovers.

The reason is worth understanding, because it explains what this company is trying to build. Recovery from a musculoskeletal injury is slow and almost impossible to perceive from inside. The pain on a Tuesday is not obviously less than the pain on the previous Tuesday. Without a measurement, the patient has only a feeling to go on, and the feeling says nothing is changing. So they skip a session, then another, then stop, and the treatment that would have worked does not, which confirms the impression that it was never working.

That is the gap an assessment and monitoring platform aims at. Range of motion recorded at each visit, strength measured rather than estimated, adherence tracked between appointments, progress shown to the patient as a line that moves. None of it is glamorous and none of it requires a breakthrough. It requires the clinician to have tools that make measurement quick enough to do routinely, which in most Indian physiotherapy practices means replacing a paper file and a judgement call.

Saxena's framing of it is the correct one: technology in this field should not be another device competing for the therapist's attention, but something that helps them demonstrate what they have achieved. A physiotherapist who can show a patient the evidence keeps that patient in treatment, and a patient who stays in treatment gets better. The commercial case and the clinical case are the same case, which is rarer in healthtech than it should be.

An $800,000 valuation is the most striking number here, and it deserves to be read plainly rather than kindly.

That is roughly ₹7.6 crore for a company incorporated four years ago. FlexifyMe raised $2.4 million in a single round, three times what the whole of Physioplus is worth. Stance Health's $1 million pre-seed exceeds the company's entire valuation. The paid-up capital on the operating entity is ₹5 lakh, and the disclosed traction is more than 1,000 patients onboarded across four years.

There are two ways to read that, and they are not mutually exclusive. The unflattering one is that four years has produced modest traction and the price reflects it. The more generous one, and probably the more accurate, is that this is an honestly priced company. A great deal of Indian seed-stage pricing is fiction agreed between two parties who both benefit from a larger number. A founder accepting $800,000 is taking a valuation that describes where the business actually is, which makes the next round easier rather than harder. Companies that raise at inflated early marks spend years growing into them, and some never do.

What the round does not buy is much. At this valuation even a substantial stake is a small cheque, and the stated uses, technology, network expansion and national presence, are three ambitions that would individually consume more than this is likely to be. Realistically this is money to keep building and to bring a strategic partner onto the register, not to expand across India.

The clinical thesis is more interesting than the finance, and it is the part worth taking seriously.

Physiotherapy has an adherence problem that is well documented and rarely discussed outside the profession. A large share of patients abandon prescribed home exercise programmes, and outcomes depend almost entirely on whether those exercises get done between appointments. The reason people stop is not laziness so much as invisibility: recovery is gradual and imperceptible day to day, nobody can feel themselves becoming eight percent better, and a patient who cannot detect progress reasonably concludes it is not working and stops attending. That conclusion then becomes self-fulfilling.

HBF's framing, from therapy delivered to recovery demonstrated, is that problem stated precisely. Measurement in physiotherapy is not an analytics feature bolted onto a booking app. It is the retention mechanism. A patient shown objective evidence of improvement keeps going, and a patient who keeps going recovers. Saxena's own version, that technology should help a clinician assess, measure and demonstrate rather than be another device, is the same argument from the practitioner's side.

The constraint the whole category lives with is that physiotherapy is hands-on. Manual therapy cannot be delivered down a video call, which means digital physiotherapy is always an adjunct to physical treatment rather than a replacement for it. The software sells on discovery, documentation, prescription and monitoring, and the money in Indian physiotherapy still changes hands in a clinic. Building for clinicians who are mostly single practitioners with limited willingness to pay for software is a slow, small-ticket business, and it is the one Physioplus has chosen.

For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.